Evaluation of the Impact of Reduced Oxygen Concentration on Embryonic Development (LO2)
Infertility
About this trial
This is an interventional treatment trial for Infertility focused on measuring Embryonic development, blastocyst stage
Eligibility Criteria
Inclusion Criteria:
- Age 18-40 years and seeking IVF with aneuploidy screening, which is our current recommendation regardless of study participation
- Anti-mullerian hormone level (AMH) > 1.0 pmol/L (an assessment of ovarian reserve)
- Must have at least two surviving embryos on day 3 of development
- Male partner with >100,000 total motile spermatozoa per ejaculate (donor sperm acceptable)
- Body Mass Index < 35
Exclusion Criteria:
- Diagnosis of endometrial insufficiency, as defined by prior cycle with maximal endometrial thickness <6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), or persistent endometrial fluid
- Use of oocyte donation
- Use of gestational carrier
- Use of sperm obtained via surgical procedure
- Presence of hydrosalpinges that communicate with endometrial cavity
- Single gene disorders, chromosomal translocations or any other disorders requiring more detailed embryo genetic analysis
- Couples seeking gender selection for family balancing
Sites / Locations
- Reproductive Medicine Associates of New Jersey
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
2% oxygen concentration in the incubator
Control
At the time that embryos are changed from "cleavage stage media" to "blastocyst stage media" on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6.
Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.